Neuralstem Trial Treats First Phase II ALS Patient

Maryland-based Neuralstem just announced that they have treated their first patient in the Phase II trial of their spinal cord-derived neural stem cells (known as NSI-566) for the treatment of ALS. Neuralstem completed their Phase I clinical trial of NSI-566 for the treatment of ALS last year. After positive Phase I trial results, Neuralstem was granted permission to move to a Phase II dose escalation and safety trial, which includes 15 patients who can be treated with up “to 40 injections and up to 400,000 cells per injection” at two centers. Karl Johe, Neuralstem’s Chairman of the Board and Chief Scientific Officer, said that “the primary goal of our Phase II trial is to identify the maximum-safe tolerated dose.”

More information about the trial, which is currently ongoing at the University of Michigan and Emory University, is available here.

Share this: